Today Enroll America partnered with the Ad Council to launch “Take Care, People,” a national multimedia public service advertising (PSA) campaign that will raise awareness, educate, and motivate uninsured Americans to get health insurance for themselves and their families under the Affordable Care Act, or ACA.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65436-enroll-america-ad-council-encourage-uninsured-sign-up-affordable-care-act
Kaléo, a privately-held pharmaceutical company, today announced the AUVI-Q® (epinephrine injection, USP) Auto-injector will be available by prescription starting February 14th, and announced AUVI-Q AffordAbility, a first-of-its-kind access program for AUVI-Q. Through this new program, patients with commercial insurance, even those with high-deductible plans, will have an out-of-pocket cost of $0. For patients who do not have government or commercial insurance, and have a household income of less than $100,000, AUVI-Q will be available free of charge. In addition, the cash price for AUVI-Q is $360 and will be available to those patients without government or commercial insurance. Each AUVI-Q prescription includes two Auto-injectors and one Trainer for AUVI-Q.
To view the multimedia release go to:
http://www.multivu.com/players/English/7981051-auvi-q-epinephrine-auto-injector-access-and-availability-launch/
Global specialty plastics provider Eastman demonstrates the dominant performance of next-generation material Eastman MXF221 copolyester as a disinfectant-ready polymer for safer healthcare environments at the Medical Design & Manufacturing (MD&M) West trade show in Anaheim, California, Feb. 6 to 8. The latest advancement in biocompatible medical-grade polymers for medical device housings and hardware, Eastman MXF221 offers unsurpassed chemical compatibility with stringent disinfectants used to combat healthcare-associated infections (HAIs) as well as improved durability and impact strength.
To view the multimedia release go to:
https://www.multivu.com/players/English/8261151-eastman-disinfectant-ready-polymer-mdm-west/
Medical, health, technology, healthcare, treatment, Richard Fechter, interview, trade show, MultiVu 8261151
The European Head and Neck Society (EHNS) and the Make Sense Campaign, today announced the launch of the Third Annual Head and Neck Cancer Awareness week (21–25 September). Through the pan-European Awareness Week, the EHNS and Make Sense Campaign promote education on head and neck cancer risk factors, disease prevention and disease signs and symptoms for both patients and healthcare professionals.
“Each year 350,000 people are diagnosed with head and neck cancer across Europe, and over half will not be alive after five years. However, if diagnosed and treated earlier, patients can have an 80 – 90% survival rate.” said Professor René Leemans, President of the EHNS and Professor and Chief of Otolaryngology – Head and Neck Surgery at VU University Medical Centre. “Through the Make Sense Campaign we are educating people about the early signs of the disease and encouraging them to seek professional help in a timely manner. Additionally, we are advocating for the best possible standards of patient care so that their outcomes can be optimised once they have been diagnosed with the disease.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7628151-support-head-neck-cancer-patients/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
Breast cancer now represents one in four of all cancers in women worldwide and touches lives every day. While experiences with the disease may vary, the desire to defeat breast cancer is universal. This year, in honor of a shared vision for a world without this disease, The Estée Lauder Companies’ Breast Cancer Awareness (BCA) Campaign celebrates the power of global solidarity by encouraging people around the world to “Take Action Together to Defeat Breast Cancer.” The 2016 BCA Campaign invites women, men and families to draw inspiration from one another and unite in action on BCAcampaign.com and social media, while supporting lifesaving breast cancer research.
Over the past two decades, The Estée Lauder Companies’ BCA Campaign, launched by the late Evelyn H. Lauder, co-creator of the Pink Ribbon and founder of the Breast Cancer Research Foundation® (BCRF), has been a leading voice for breast cancer awareness around the world, igniting a global movement that has helped save millions of lives and fund innovative breast cancer research. Today, The BCA Campaign is active in more than 70 countries and has raised more than $65 million to support global research, education and medical services, with more than $50 million funding 200 BCRF medical research grants worldwide over the past 22 years. These funds help accelerate critical research across wide-ranging areas such as tumor biology, heredity and ethnicity, lifestyle and prevention, treatment, survivorship and metastasis. Around the world, The BCA Campaign partners with more than 60 breast cancer organizations focused on breast cancer research, education and medical services. This year, The BCA Campaign is committed to raising $6 million in support of its mission to defeat breast cancer through education and medical research.
To view the multimedia release go to:
http://www.multivu.com/players/English/7935851-estee-lauder-bca-campaign-2016/
LLNS, a leading healthcare communications company and part of Diversified Agency Services (DAS), is pleased to announce that Sharon Callahan, CEO of LLNS, has been recognized by the Women’s Venture Fund with its “Highest Leaf Award”. The award celebrates exceptional women who have demonstrated remarkable business leadership, developed a vision for business success and made outstanding contributions to their respective industries.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7234651-llns-sharon-callahan-business-leadership-women-s-venture-fund-healthcare
Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CCSS), a National Cancer Institute-funded resource for late-effects research, led by investigators at St. Jude Children’s Research Hospital.
“This is the first comprehensive study to demonstrate how changes in treatments over time have impacted the occurrence of late effects experienced by childhood cancer survivors,” said Todd Gibson, Ph.D., assistant member of the Department of Epidemiology and Cancer Control at St. Jude. “We found the 15-year cumulative incidence of people reporting at least one severe health condition decreased from 12.7 percent among childhood cancer survivors diagnosed in the 1970s to 10.1 percent for those diagnosed in the 1980s to 8.8 percent in the 1990s–a statistically significant decline.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7924756-st-jude-childhood-cancer-survivorship-asco-2017/
A Harvard School of Dental Medicine symposium recently featured data from United Concordia Dental’s landmark study as compelling evidence on the costly impact of poor oral health on overall wellness.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7052551-united-concordia-dental-research-featured-at-harvard-university-symposium/
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Every 23 seconds, someone in the United States is diagnosed with diabetes. It's estimated that one in 11 Americans has the disease—more than 29 million people—and another 86 million have prediabetes and are at risk for developing type 2 diabetes. The numbers alone are staggering, and the people affected by the disease include those who have diabetes and their friends, family, caregivers and communities.
American Diabetes Month®, observed by the American Diabetes Association® (Association) every November, is a time to focus the nation's attention on the many people who are affected by diabetes and to raise the urgency about the need to address diabetes. To help spark a national conversation, the Association is asking people to share their stories about what it truly means to live with diabetes with a new campaign, This Is Diabetes™.
http://www.multivu.com/players/English/7711431-american-diabetes-month-thisisdiabetes/
Results from two national surveys of patients receiving chemotherapy and pharmacists, conducted by the Hematology/Oncology Pharmacy Association (HOPA) in collaboration with Eisai Inc.,* found that 83% of patients receiving chemotherapy who have experienced chemotherapy-induced nausea and vomiting (CINV) believe it is a side effect with which they must live. Results also showed that 95% of cancer patients surveyed believe that CINV has, at some point, had an impact on their daily lives. These national surveys are part of the Time to Talk CINV™ campaign, which aims to increase awareness among patients and caregivers about CINV prevention and the importance of speaking with their pharmacist and full healthcare team about this often preventable side effect.
“The survey results underscore the confusion patients who are undergoing chemotherapy have about CINV and the need for them to understand that there are ways to manage their symptoms so that they do not have to needlessly suffer with CINV,” said Scott Soefje, PharmD, MBA, BCOP, President, Hematology/Oncology Pharmacy Association (HOPA) and Director of Pharmacy at the University Medical Center Brackenridge in Austin, TX. “It is imperative that patients discuss CINV prevention early in treatment and with all members of the health care team, including pharmacists.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7560331-time-to-talk-cinv/
